Erratum: "Giant cell arteritis: A systemic vascular disease" (Vascular Medicine (2008) vol. 13 (127-140) 10.1177/1358863x07085499);Giant cell arteritis: A systemic vascular disease

Vascular Medicine

Volumn 13, Issue 2, 2008, Pages 127-140

  Tatò, Federico ^a   Hoffmann, Ulrich ^a  

^a Gefaesszentrum Muenchner Freihet   (Germany)

Author keywords

Duplex sonography; Extracranial involvement; Fluorine 18 desoxyglucose positron emission tomography; Giant cell arteritis; Large vessel vasculitis; Magnetic resonance imaging

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; AORTA ANEURYSM; AORTA DISSECTION; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOGRAPHY; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; LIMB ISCHEMIA; LIMB SALVAGE; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOGRAPHY, DIGITAL SUBTRACTION; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; FLUORODEOXYGLUCOSE F18; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; MAGNETIC RESONANCE ANGIOGRAPHY; PERIPHERAL VASCULAR DISEASES; PHYSICAL EXAMINATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, COLOR; VASCULAR SURGICAL PROCEDURES;

EID: 46849090492     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X08096166     Document Type: Erratum

References (86)

1. Salvarani, C, Cantini, F, Boiardi, L, Hunder, GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-271.
2. Weyand, CM, Goronzy, JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003; 139: 505-515.
3. Lawrence, RC, Helmick, CG, Arnett, FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799.
4. Noltorp, S, Svensson, B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991; 9: 351-355.
5. Franzén, P, Sutinen, S, von Knorrig, J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol 1992; 19: 273-276.
6. Hunder, GG. The early history of giant cell arteritis and polymyalgia rheumatica: first description to 1970. Mayo Clin Proc 2006; 81: 1071-1083.
7. Hunder, GG, Ward, LM, Burbank, MK. Giant-cell arteritis producing an aortic arch syndrome. Ann Intern Med 1967; 66: 578-582.
8. Klein, RG, Hunder, GG, Stanson, AW, Sheps, SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83: 806-812.
9. Perruquet, JL, Davis, DE, Harrington, TM. Aortic arch arteritis in the elderly. Arch Intern Med 1986; 146: 289-291.
10. Neunninghoff, DM, Hunder, GG, Christianson, TJH, McClelland, RL, Matteson, EL. Incidence and predictors of large-artery complications (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3522-3531.
11. Weyand, CM, Goronzy, JJ. Medium- and large-vessel vasculitis. N Eng J Med 2003; 349: 160-169.
12. Barack, A, Martinez-Taboada, V, Stanson, A, Goronzy, JJ, Weyand, CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999; 42: 311-317.
13. Arend, WP, Michel, BA, Bloch, DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134.
14. Kerr, GS, Hallahan, CW, Giordano, J, et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919-929.
15. Michel, BA, Arend, WP, Hunder, GG. Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. J Rheumatol 1996; 23: 106-111.
16. Lie, JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathological documentation. Semin Arthritis Rheum 1995; 24: 422-431.
17. Evans, JM, O'Fallon, WM, Hunder, GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995; 122: 502-507.
18. Evans, JM, Bowles, CA, Bjornsson, J, Mullany, CJ, Hunder, GG. Thoracic aortic aneurysm and rupture in giant cell arteritis: a descriptive study of 41 cases. Arthritis Rheum 1994; 37: 1539-1547.
19. Bongartz, T, Matteson, EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006; 18: 10-17.
20. O'Brien, PK, Pudden, AJ. Peripheral arterial insufficiency due to giant cell arteritis. Can J Surg 1978; 21: 441-442.
21. Garcia Vasquez, JM, Carreira, JM, Seoane, C, Vidal, JJ. Superior and inferior limb ischemia in giant cell arteritis: angiography follow-up. Clin Rheumatol 1999; 18: 61-65.
22. Le Hello, C, Levesque, H, Jeanton, M, et al. Lower limb giant cell arteritis and temporal arteritis: follow-up of 8 cases. J Rheumatol 2001; 28: 1407-1412.
23. Tatò, F, Hoffmann, U. Clinical presentation and vascular imaging in giant cell arteritis of the femoro-popliteal and tibio-peroneal arteries. J Vasc Surg 2006; 44: 176-182.
24. Weyand, CM, Wagner, AD, Bojornsson, J, Goronzy, JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant-cell arteritis. J Clin Invest 1996; 98: 1642-1649.
25. Rodríguez-Pla, A, Bosch-Gil, JA, Rosselló-Urgell, J, Huguet-Redecilla, H, Stone, JH, Vilardell-Tarres, M. Metalloproteinase-2 and -9 in giant cell arteritis. Involvement in vascular remodeling. Circulation 2005; 112: 264-269.
26. Kaiser, M, Weyand, CM, Bjornsson, J, Goronzy, JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41: 623-633.
27. Kaiser, M, Younge, B, Bjornsson, J, Goronzy, JJ, Weyand, CM. Formation of new vasa vasorum in vasculitis: production of angiogenetic cytokines by multinucleated giant cells. Am J Pathol 1999: 155: 765-774.
28. Gabriel, SE, O'Fallon, WM, Achkar, AA, Lie, JT, Hunder, GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93-96.
29. Salvarani, C, Silingardi, M, Ghirarduzzi, A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002; 137: 231-238.
30. Lederle, FA, Simel, DL. Does this patient have abdominal aortic aneurysm? JAMA 1999; 281: 77-82.
31. Hunder, GG, Bloch, DA, Michel, BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128.
32. Salvarani, C, Hunder, GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population based study. Arthritis Rheum 2001; 45: 140-145.
33. Hayreh, SS, Podhajsky, PA, Raman, R, Zimmerman, B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285-296.
34. Parikh, M, Miller, NR, Lee, AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006; 113: 1842-1845.
35. Salvarani, C, Cantini, F, Boiardi, L, Hunder, GG. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 2003; 21 (suppl 32): S23-S28.
36. Weyand, C, Fulbright, JW, Hunder, GG, Evans, JM, Goronzy, JJ. Treatment of giant cell arteritis. Interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041-1048.
37. Schmidt, WA, Kraft, HE, Vorpahl, K, Volker, L, Gromnika-Ihle, EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-1342.
38. Schmidt, WA, Gromnica-Ihle, E. Duplex ultrasonography in temporal arteritis. Ann Intern Med 2003; 138: 609.
39. Karassa, FB, Matsagas, MI, Schmidt, WA, Ioannidis, JPA. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005; 142: 359-369.
40. Schmidt, WA, Kraft, HE, Borkowski, A, Gromnika-Ihle, EJ. Color duplex ultrasonography in large-vessel giant cell arteritis. Scand J Rheumatol 1999; 28: 374-376.
41. Schmidt, WA, Natusch, A, Moeller, DE, Vorpahl, K, Gromnika-Ihle, EJ. Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. Clin Exp Rheumatol 2002; 20: 309-318.
42. Reinhard, M, Schmidt, D, Schumacher, M, Hetzel, A. Involvement of the vertebral arteries in giant cell arteritis mimicking vertebral dissection. J Neurol 2003; 250: 1006-1009.
43. Kolossvary, E, Kollar, A, Pinter, H, et al. Bilateral axillobrachial and external carotid artery manifestation of giant cell arteritis: important role of color duplex ultrasonography in the diagnosis. Int Angiol 2005; 24: 202-205.
44. Schmidt, WA, Blockmans, D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005; 17: 9-15.
45. Park, JH, Chung, JW, Im, JG, Kim, SK, Park, YB, Han, MC. Takayasu arteritis: evaluation of mural changes in the aorta and pulmonary artery with CT angiography. Radiology 1995; 196: 89-93.
46. Yamada, I, Nakagawa, T, Himeno, Y, Numano, F, Shibuya, H. Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. Radiology 1998; 209: 103-109.
47. Yoshida, S, Akiba, H, Tamakawa, M, et al. The spectrum of findings in supra-aortic Takayasu's arteritis as seen on spiral CT angiography and digital subtraction angiography. Cardiovasc Intervent Radiol 2001; 24: 117-121.
48. Choe, YH, Han, BK, Koh, EM, Kim, DK, Do, YS, Lee, WR. Takayasu's arteritis: assessment of disease activity with contrast-enhanced MR imaging. AJR Am J Roentgenol 2000; 175: 505-511.
49. Tso, E, Flamm, SD, White, RD, Schwartzman, PR, Mascha, E, Hoffman, GS. Takayasu arteritis. Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46: 1634-1642.
50. Mcller, J, Grabbe, E, Becker, W, Vosshenrich, R. Value of F-18 FDG hybrid camera PET and MRI in early Takayasu aortitis. Eur Radiol 2003; 13: 400-405.
51. Desai, MY, Stone, JH, Foo, TK, Hellmann, DB, Lima, JAC, Bluemke, DA. Delayed contrast-enhanced MRI of the aortic wall in Takayasu's arteritis: initial experience. Am J Radiol 2005; 184: 1427-1431.
52. Narvaez, J, Narvaez, JA, Nolla, JM, Sirvent, E, Reina, D, Valverde, J. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology 2005; 44: 479-483.
53. Markl, M, Uhl, M, Wieben, O, et al. High resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis. J Magn Reson Imaging 2006; 24: 423-427.
54. Aluquin, VP, Albano, SA, Chan, F, et al. Magnetic resonance imaging in the diagnosis and follow up of Takayasu's arteritis in children. Ann Rheum Dis 2002; 46: 1634-1642.
55. Bley, TA, Ness, T, Warnatz, K, et al. Influence of corticosteroid treatment on MRI findings in giant cell arteritis. Clin Rheumatol 2007; 26: 1541-1543.
56. Stanson, AW, Klein, RG, Hunder, GG. Extracranial angiographic findings in giant cell (temporal) arteritis. AJR Am J Roentgenol 1976; 127: 957-963.
57. Slovut, DP, Olin, JW. Fibromuscular dysplasia. N Engl J Med 2004; 350: 1862-1871.
58. Blockmans, D, Knockaert, D, Maes, A, et al. Clinical value of [18F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32: 191-196.
59. Turlakow, A, Yeung, HWD, Pui, J, et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001; 161: 1003-1007.
60. Belhocine, T, Blockmans, D, Hustinx, R, Vandevivere, J, Mortelmans, L. Imaging of large vessel vasculitis with 18FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging 2003; 30: 1305-1313.
61. Webb, M, Chambers, A, Al-Nahhas, A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004; 31: 627-634.
62. Brodmann, M, Lipp, RW, Passath, A, Seinost, G, Pabst, E, Pilger, E. The role of 2-18F-fluoro-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology 2004; 43: 241-242.
63. Blockmans, D, De Ceuninck, L, Vanderschuren, S, Knockaert, D, Mortelmans, L, Bobbaers, H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006; 55: 131-137.
64. Knockaert, DC, Vanderschueren, S, Blockmans, D. Fever of unknown origin in adults: 40 years on. J Intern Med 2003; 253: 263-275.
65. Meller, J, Strutz, F, Scheel, A, et al. Early diagnosis and follow-up of aortitis with 18F-FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003; 30: 730-736.
66. Tatò, F, Weiss, M, Hoffmann, U. [Takayasu's arteritis without manifest arterial stenoses as a cause of fever of unknown origin.] Dtsch Med Wochenschr 2006; 131: 1727-1730.
67. Blockmans, D, Stroobants, S, Maes, A, Mortelmans, L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108: 246-249.
68. Yun, M, Yeh, D, Arujo, LI, Jang, S, Newberg, A, Alavi, A. F-18 FDG uptake in the large arteries. A new observation. Clin Nucl Med 2001; 26: 314-319.
69. Lederman, RJ, Raylman, RR, Fisher, SJ, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun 2001; 22: 747-753.
70. Mazlumzadeh, M, Hunder, GG, Easley, KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controled, randomized, prospective clinical trial. Arthritis Rheum 2006; 54: 3071-3074.
71. Chan, CC, Paine, M, O'Day, J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061-1064.
72. Hayreh, SS, Zimmerman, B. Management of giant cell arteritis. Our 27-year clinical study: new light in old controversies. Ophthalmologica 2003; 217: 239-259.
73. Spiera, RF, Mitnick, HJ, Kupersmith, M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495-501.
74. Hoffman, GS, Cid, MC, Hellmann, DB, et al. for the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-1318.
75. Jover, JA, Hernandez-Garcia, C, Morado, IC, Vargas, E, Banares, A, Fernandez-Gutierrez, B. Combined treatment of giant cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-114.
76. Hoffman, GS, Merkel, PA, Brasington, RD, Lenschow, DJ, Liang, P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-2304.
77. Tatò, F, Rieger, J, Hoffmann, U. Refractory Takayasu's arteriitis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005; 24: 304-307.
78. Hoffman, GS, Cid, MC, Rendt-Zagar, KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007; 146: 621-630.
79. Nesher, G, Berkun, Y, Mates, M, Baras, M, Rubinow, A, Sonnenblick, M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-1337.
80. Lee, MS, Smith, SD, Galor, A, Hoffman, GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306-3309.
81. Weyand, CM, Kaiser, M, Yang, H, Younge, B, Goronzy, JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-466.
82. Liang, P, Hoffman, GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005; 17: 16-24.
83. Fava, MP, Foradori, GB, Garcia, CB, et al. Percutaneous transluminal angioplasty in patients with Takayasu arteritis: five year experience. J Vasc Intervent Radiol 1993; 4: 649-652.
84. Both, M, Aries, PM, Muller-Hulsbeck, S, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis 2006: 65: 1124-1130.
85. Abu Rahma, AF, Thaxton, L. Temporal arteritis: diagnostic and therapeutic considerations. Am Surg 1996; 62: 449-451.
86. Soury, P, Brisset, D, Saliou, C, et al. Arterial lesions of the upper limbs in horton disease. Surgical revascularization by bilateral carotid-humeral bypass. Presse Med 1997; 26: 1478-1480.